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Abstract
Magnetic resonance imaging of a girl with giant axonal neuropathy revealed a progressive white matter disease. In close agreement with
histopathological features reported previously, localized proton magnetic resonance spectroscopy at 9 and 12 years of age indicated a specific
damage or loss of axons (reduced N-acetylaspartate and N-acetylaspartylglutamate) accompanied by acute demyelination (elevated choline-
containing compounds, myo-inositol, and lactate) in white matter as well as a generalized proliferation of glial cells (elevated choline-
containing compounds and myo-inositol) in both gray and white matter.
q 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Amongst the peripheral neuropathies in childhood, giant
axonal neuropathy (GAN) shows some unique clinical and
morphological features. GAN is a generalized disorder of
cytoplasmatic intermediate filaments with accumulation of
ovoid aggregates in different cell types [1–3]. Early observa-
tions [4,5] depicted clinical features of a peripheral neuropathy
in children with ‘remarkably kinky hair’ [4]. Subsequent
reports stressed the involvement of the central nervous system
(CNS) as revealed by clinical features [6] as well as neuror-
adiological [7,8], neurophysiological [9], and neuropathologi-
cal investigations [10,11]. The gene for GAN was mapped to
chromosome 16q24 [12]. Recently, the gene GAN has been
identified and found to encode for a novel, ubiquitously
expressed protein named gigaxonin [13].
Here, we used localized proton magnetic resonance spec-
troscopy (MRS) to further characterize the involvement of
the CNS by assessing metabolic alterations in different brain
regions in a girl with GAN at the age of 9 years and in a
follow-up investigation three years later.
2. Clinical report
The clinical, neurophysiological, and histopathological
features of this patient have been described previously
[14]. Briefly, muscular hypotonia was noticed at 6 months
of age. Her motor development was slightly delayed, she sat
unsupported at 15 months, and walked freely at 2 years. She
showed a broad-based, atactic gait and developed distal
weakness and wasting in her lower limbs. Between the
third and fourth year her gait deteriorated and she lost inde-
pendent walking, standing, and crawling successively over
the years. At the age of 4 years clinical and neurophysiolo-
gical investigations pointed to an axonal polyneuropathy. A
sural nerve biopsy was performed and the neuropathological
diagnosis of GAN was established.
On re-examination at the age of 9 years, a slowly progres-
sive decline of her psychomotor abilities was evident. She
showed muscular hypotonia, marked weakness of arms and
legs and distal wasting of lower limbs. By that time she was
wheelchair dependent, hardly able to lift her arms and
unable to lift her legs against gravity. Plantar reflexes as
well as tendon reflexes in arms and legs were absent.
There were mild contractures of her knees and severe
kyphoscoliosis. Facial weakness, bilateral ptosis, and a
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Fig. 1. White matter abnormalities in (A–D) T2-weighted MRI (FSE, TR=TE ¼ 2:625=98 ms, flip angles ¼ 908=1208) and (E–H) T1-weighted MRI (3D
FLASH, TR=TE ¼ 15=4 ms, flip angle ¼ 208) of the patient with giant axonal neuropathy at the age of 9 years (left column) and 12 years (right column). The
boxes indicate standardized volumes of interest for proton MRS of paramedian parietal gray matter (12.5 ml, A,B), parieto-occipital white matter (4.1 ml, C–
F), and central cerebellum (8.0 ml, G,H).
mild gaze-dependent vertical nystagmus were observed.
Optic discs were pale, and visual acuity was diminished.
During the following 3 years she became increasingly
incapacitated by weakness and ataxia. At the age of 12
years, she had great difficulties in moving her wheelchair
and with control of her head. Dysarthria and dysphagia were
apparent. She was attentive and understanding well, though
delayed in her response.
Neurophysiological investigations were performed
repeatedly during the course of the disease. Nerve conduc-
tion studies revealed reduction of amplitudes or absence of
compound muscle action potentials, absence of nearly all
sensory responses, and mild to moderately reduced conduc-
tion velocities. Visual evoked responses were increasingly
delayed. Auditory brainstem responses were delayed and
finally absent at the age of 11 years. Median nerve somato-
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Fig. 2. Proton MRS (TR=TE=TM ¼ 6000=20=10 ms, 64 accumulations) of gray matter (GM), right (R) and left (L) white matter (WM), and cerebellum (Cereb)
of the patient with giant axonal neuropathy at the age of 9 years (left column) and 12 years (right column). Major metabolite resonances refer to N-
acetylaspartate and N-acetylaspartylglutamate (tNAA), creatine and phosphocreatine (tCr), choline-containing compounds (Cho), myo-inositol (Ins), and
lactate (Lac).
sensory evoked responses (SER) were delayed, tibial nerve
SER were absent early in the course.
Mutation analysis of the gigaxonin gene was performed by
direct sequencing of the entire coding region of the GAN gene.
This revealed a homozygous point mutation at nt281 of the
consensus sequence (A281G), predicting a codon change from
Gln to Arg at residue 94 (Q94A). However, this mutation
results in a AG/gt to GG/gt change at the intron 3 donor splice
site, and may result in an abnormally spliced transcript.
3. Methods
Written informed consent was obtained from the parents.
Fully relaxed short-echo time proton MR spectra were
acquired with use of a single-voxel stimulated echo acquisi-
tion mode localization sequence [15]
(TR=TE=TM ¼ 6000=20=10 ms, 64 accumulations) and the
standard imaging headcoil at 2.0 T (Siemens Magnetom
Vision, Erlangen, Germany). Volumes of interest (VOI)
were selected from T1-weighted (3D FLASH) and T2-
weighted (FSE) images, with sizes ranging from 4.1 to
12.5 ml (Fig. 1). Spectral evaluation and quantification of
absolute metabolite concentrations were accomplished with
use of LCModel, a user-independent fitting routine based on
a library of calibrated model spectra of all individual
compounds. Details have been described elsewhere [16].
Previous studies of regional age dependencies of cerebral
metabolites [17] provided age-matched controls.
Major detectable metabolites include the neuroaxonal
markers [18] N-acetylaspartate and N-acetylaspartylgluta-
mate (tNAA), creatine and phosphocreatine (tCr) as ubiqui-
tous compounds linked to energy metabolism, choline-
containing compounds (Cho) involved in membrane turn-
over, the glial (astrocytic) marker [19] and brain osmolyte
myo-inositol (Ins), and lactate (Lac) as the intermediate
product of nonoxidative glucose consumption. More speci-
fically, Cho is highly concentrated in oligodendrocytes as
indicated by its severe reduction in proton MRS of hypo-
myelination such as Pelizaeus–Merzbacher disease [20]. It
mainly represents contributions from phosphorylcholine
and phosphorylethanolamine as precursor molecules for
membrane synthesis as well as glycerophosphorylcholine
and glycerophosphorylethanolamine as the corresponding
membrane degradation products. Elevated Cho and Ins
concentrations therefore may indicate both glial prolifera-
tion (e.g. in brain tumors), and cellular disruption (e.g. in
demyelination), respectively.
4. Results
In comparison with a preceding investigation at the age of
4 years, MRI at the age of 9 years revealed a distinct progres-
sion of white matter abnormalities. There was slight dilation
of lateral ventricles, predominantly of posterior horns, and
atrophy of the vermis cerebelli. Fig. 1 (left column) demon-
strates diffuse changes of both supratentorial and infratentor-
ial white matter with almost homogenous hyperintensity on
T2-weighted images (Fig. 1A,C) and an inhomogeneous,
moderately low signal in T1-weighted images (Fig. 1E,G).
U-fibers and corpus callosum were spared. A follow-up MRI
study at the age of 12 years (Fig. 1, right column) showed a
more pronounced dilation of internal and external CSF
spaces as well as a further reduction of unaffected white
matter. Especially lesions of cerebellar white matter had
markedly increased (Fig. 1G,H). Although the images have
been chosen to properly indicate the locations selected for
MRS and therefore are suboptimal for demonstration of
enlargement of ventricles, progressive widening of external
CSF spaces is recognizable in temporo-parietal cortex (Fig.
1D,F) and cerebellum (Fig. 1H).
Fig. 2 depicts MR spectra from four different brain
regions obtained at the age of 9 and 12 years. Visual inspec-
tion reveals reduced tNAA as well as elevated Cho in white
matter and cerebellum. Pertinent findings confirm the MRI
observation of predominant disturbances in cerebral and
cerebellar white matter. The quantitative analysis of abso-
lute metabolite concentrations in Table 1 provides a more
detailed picture of metabolic alterations. In particular, at the
age of 9 years, cerebral white matter from both hemispheres
showed a marked reduction of tNAA (244%) accompanied
by increased concentrations of Cho (156%), Ins (1100%),
and Lac. Similar though even more pronounced alterations
were found in cerebellum with an additional elevation of tCr
(117%). Also cortical gray matter, which appeared normal
on MRI, presented with metabolic alterations. Whereas the
gray matter level of tNAA was normal, the concentrations of
Cho (173%), Ins (179%), and tCr (117%) were enhanced.
When comparing these results with those of the follow-up
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Table 1
Cerebral metabolite concentrations (mM) of the patient with GAN and of
age-matched controls (mean ^ SD)a [17]
tNAA tCr Cho Ins Lac
Gray matter
9y 8m 8.7 7.6* 1.9** 7.7** 1.6
12y 8m 9.0 8.1** 1.5* 5.8* –
Control (n ¼ 22) 9.0 ^ 0.8 6.5 ^ 0.5 1.1 ^ 0.2 4.3 ^ 0.6 –
White matter
9y 8m RPO 4.1** 4.7 2.4** 6.9* 3.0
9y 8m LPO 4.7** 5.0 2.6** 9.1** 2.0
12y 8m RPO 4.5** 4.8 1.9 5.7* –
12y 8m LPO 4.6** 5.2 2.1* 6.0* –
Control (n ¼ 12) 7.9 ^ 0.6 4.8 ^ 0.4 1.6 ^ 0.2 3.9 ^ 1.2 –
Cerebellum
9y 8m 3.0** 10.1* 3.6** 12.0** 2.6
12y 8m 2.3** 7.4 2.9** 7.2* 4.1
Control (n ¼ 3) 7.5 ^ 1.0 8.6 ^ 0.7 2.0 ^ 0.2 4.8 ^ 0.9 –
a y, years; m, months; RPO, right parieto-occipital; LPO, left parieto-
occipital. *. 2 SD from control; **. 4 SD from control.
examination, the latter exhibited less increased concentra-
tions of Cho and Lac but otherwise a similarly abnormal
metabolic pattern.
5. Discussion
The MRI findings in our patient with GAN are in line
with the features reported in the literature, for example, in
cortical and cerebellar white matter of a 21-year-old woman
with CNS symptoms including seizures but only mild symp-
toms of peripheral neuropathy [7]. To the best of our knowl-
edge, the present proton MRS study is the first attempt to
characterize metabolic alterations in the brain of a patient
with GAN and CNS involvement.
As a main finding the reduction of tNAA in white matter
and cerebellum suggests a damage or even loss of neuroax-
onal tissue. The very strong elevation of Cho and Ins at the
age of 9 years probably reflects both glial proliferation and
active demyelination. Glial proliferation may be predomi-
nantly ascribed to astrocytes because of the pronounced
increase of Ins. The assumption of active demyelination
subsequent to axonal damage is also supported by the detec-
tion of Lac, which most likely indicates the anaerobic meta-
bolism of infiltrating macrophages removing cellular
decomposition products during acute phases of the disease.
Cerebral white matter at the age of 12 years showed
unchanged low tNAA, normalized Lac, and slightly less
increased Cho and Ins. These metabolic disturbances,
consistent with fading of active demyelination, hint to a
regional stabilization. Similarly, elevations of Cho and Ins
in cerebellum are less pronounced than at 9 years, but the
ongoing atrophy as detected by MRI and the strong increase
of Lac point to progressive cellular disruption in cerebel-
lum. Accordingly tNAA concentration remains close to
detectability. These findings are in line with clinical
progression of the disease, dominated by almost total loss
of all major motor functions, progressive ataxia and brain-
stem dysfunction as well as clear signs of dementia. The
metabolic characterization of cortical gray matter is in line
with neuronal preservation (normal tNAA) and glial prolif-
eration (increased Cho and Ins). Together these effects
result in a higher cell density, which leads to elevated tCr
values, because of its even distribution amongst neuronal
and glial cells.
The metabolic pattern of strong disturbances in white
matter and comparatively mild alterations in gray matter
are in line with the clinical picture of a white matter disease
dominated by spasticity and ataxia interfering with the long-
standing signs of peripheral neuropathy. Only late in the
course symptoms of dementia became apparent. Clinical
as well as MRI and MRS follow-up demonstrated a
cranio-caudal progress of the disease with increasing
dysfunction of cerebellum and brainstem.
The metabolic abnormalities obtained in vivo are in
excellent agreement with histopathological findings
reported previously. Postmortem studies of CNS involve-
ment in GAN have been performed in several patients [10].
The detailed neuropathological report by Thomas et al. of a
patient who died at the age of 18 years described a normal
brain weight, slight dilation of ventricles, and thinning of
corpus callosum [11]. White matter of centrum semiovale
was grayish discolored and showed additional spongy
changes in cerebellum. Subcortical arcuate fibers were
macroscopically well preserved. There was a distal axono-
pathy most severely affecting the corticospinal tracts,
middle cerebellar peduncles, and posterior columns, as
well as olivocerebellar degeneration. In line with the MRS
findings of our patient presented here, histological examina-
tion of cerebral cortex revealed increased numbers of astro-
cytes and scattered Rosenthal fibers. The cerebral white
matter was severely gliotic containing only few giant
axons. Optic nerves and tracts showed fiber loss and gliosis.
Giant axons and Rosenthal fibers were found in pons and
medulla. The cerebellar white matter was much depleted of
nerve fibers and consisted mainly of astrocytic processes
and Rosenthal fibers. Kretzschmar et al. reported similar
histopathological features [10] on the original case of
Berg et al. [4], and emphasized the presence of Rosenthal
fibers in CNS as a conspicuous and probably regular finding
in typical cases of GAN.
In summary, this proton MRS study of GAN provides an
in vivo assessment of metabolic alterations in various
regions of the brain that reflect histopathological changes
such as neuroaxonal damage or loss, active demyelination,
glial proliferation, and enhanced cellular density in close
agreement with the results of postmortem analyses. In a
more general perspective, the disturbed metabolite pattern
found in white matter resembles the typical abnormalities
observed in leukodystrophies with active demyelination,
e.g. metachromatic leukodystrophy [21] and Krabbe’s
disease [16].
Acknowledgements
P.J.W.P. was supported by a fellowship of the European
Community (ERBCH-BGCT 940722).
References
[1] Prineas JW, Ouvrier RA, Wright RG, Walsh JC, McLeod JG. Giant
axonal neuropathy – a generalized disorder of cytoplasmic microfila-
ment formation. J Neuropathol Exp Neurol 1976;35:458–470.
[2] Pena SD. Giant axonal neuropathy: an inborn error of organization of
intermediate filaments. Muscle Nerve 1982;5:166–172.
[3] Ouvrier RA. Giant axonal neuropathy. A review. Brain Dev
1989;11:207–214.
[4] Berg BO, Rosenberg SH, Asbury AK. Giant axonal neuropathy.
Pediatrics 1972;49:894–899.
[5] Carpenter S, Karpati G, Andermann F, Gold R. Giant axonal neuro-
pathy. A clinically and morphologically distinct neurological disease.
Arch Neurol 1974;31:312–316.
[6] Igisu H, Ohta M, Tabira T, Hosokawa S, Goto I, Kuroiwa Y. Giant
K. Brockmann et al. / Brain & Development 25 (2003) 45–50 49
axonal neuropathy. A clinical entity affecting the central as well as the
peripheral nervous system. Neurology 1975;25:717–721.
[7] Lampl Y, Eshel Y, Ben-David E, Gilad R, Sarova-Pinhas I, Sandbank
U. Giant axonal neuropathy with predominant central nervous system
manifestations. Dev Med Child Neurol 1992;34:164–169.
[8] Richen P, Tandan R. Giant axonal neuropathy: Progressive clinical
and radiologic CNS involvement. Neurology 1992;42:2220–2222.
[9] Majnemer A, Rosenblatt B, Watters G, Andermann F. Giant axonal
neuropathy: central abnormalities demonstrated by evoked potentials.
Ann Neurol 1986;19:394–396.
[10] Kretzschmar HA, Berg BO, Davis RL. Giant axonal neuropathy. A
neuropathological study. Acta Neuropathol (Berl) 1987;73:138–144.
[11] Thomas C, Love S, Powell HC, Schultz P, Lampert PW. Giant axonal
neuropathy: correlation of clinical findings with postmortem neuro-
pathology. Ann Neurol 1987;22:79–84.
[12] Flanigan KM, Crawford TO, Griffin JW, Goebel HH, Kohlschu¨tter A,
Ranells J, et al. Localization of the giant axonal neuropathy gene to
chromosome 16q24. Ann Neurol 1998;43:143–148.
[13] Bomont P, Cavalier L, Blondeau F, Ben Hamida C, Belal S, Tazir M,
et al. The gene encoding gigaxonin, a new member of the cytoskeletal
BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nat
Genet 2000;26:370–374.
[14] Treiber-Held S, Budjarjo-Welim H, Riemann D, Richter J, Kretzsch-
mar HA, Hanefeld F. Giant axonal neuropathy: a generalized disorder
of intermediate filaments with longitudinal grooves in the hair. Neuro-
pediatrics 1994;25:89–93.
[15] Frahm J, Michaelis T, Merboldt KD, Bruhn H, Gyngell ML, Ha¨nicke
W. Improvements in localized proton NMR spectroscopy of human
brain. Water suppression, short echo times, and 1 ml resolution. J
Magn Reson 1990;90:464–473.
[16] Frahm J, Hanefeld F. Localized proton magnetic resonance spectro-
scopy of brain disorders in childhood. In: Bachelard HS, editor.
Magnetic resonance spectroscopy and imaging in neurochemistry,
New York: Plenum, 1997. pp. 329–402.
[17] Pouwels PJ, Brockmann K, Kruse B, Wilken B, Wick M, Hanefeld F,
et al. Regional age dependence of human brain metabolites from
infancy to adulthood as detected by quantitative localized proton
MRS. Pediatr Res 1999;46:474–485.
[18] Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature
review of a compound prominent in 1H NMR spectroscopic studies
of the brain. Neurosci Biobehav Rev 1989;13:23–31.
[19] Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR
studies on the energy metabolism of glial and neuronal cells. Dev
Neurosci 1993;15:289–298.
[20] Pouwels P, Hanefeld F, Frahm J. Proton MRS in Pelizaeus–Merzba-
cher disease. Neuropediatrics 1997;28:355–356.
[21] Kruse B, Hanefeld F, Christen HJ, Bruhn H, Michaelis T, Ha¨nicke W,
et al. Alterations of brain metabolites in metachromatic leukodystro-
phy as detected by localized proton magnetic resonance spectroscopy
in vivo. J Neurol 1993;241:68–74.
K. Brockmann et al. / Brain & Development 25 (2003) 45–5050
